<DOC>
	<DOCNO>NCT02005133</DOCNO>
	<brief_summary>To assess use aflibercept 2 year period VEGF inhibitor naive prior treat wet AMD patient manage 'real wold ' clinic setting .</brief_summary>
	<brief_title>A Prospective , Observational , Multicentre , 2 Year Study Evaluating Use Eylea ( Aflibercept ) Treatment Neovascular ( Wet ) Age-related Macular Degeneration UK NHS Opthalmology Clinics</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Age great equal 50 year Active choroidal neovascularisation secondary AMD one eye opinion investigator benefit treatment aflibercept Subject willing able provide inform consent Patients must prior use either bevacizumab aflibercept Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Wet age-related macular degeneration</keyword>
</DOC>